A majority of an FDA advisory panel believes the agency should update the label for the breast cancer drug tamoxifen to include information about CYP2D6 genotype testing, but the panelists have not reached a consensus on certain details of the issue.
 
Specifically, the FDA’s Pharmaceutical Science Clinical Pharmacology Subcommittee, which met Oct. 18, was split over whether the label should “recommend” the genetic test or make it an “option” for health care providers and patients to discuss.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.